Biogen Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $31.03. The key difference: Biogen Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| BIIB | TMF | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.63 | $44.14 |
52-Week Low | $128.93 | $30.59 |
Enterprise Value | $37.20B | — |
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $30.93 with a 0.95% daily gain. Technical indicators show a bearish trend with moving averages and ADX signaling sell conditions, while oscillators remain neutral. The ETF faces significant fundamental challenges with unavailable valuation and profitability metrics, reflecting its leveraged structure that amplifies both gains and losses in long-duration treasuries.
The outlook for TMF remains high-risk due to its daily leverage reset mechanism, making it unsuitable for long-term holdings. While some analysts see potential at bond market lows, the dominant view cautions against current purchases given the substantial erosion of value over time, with $10,000 invested five years ago now worth approximately $1,527 according to 24/7 Wall Street analysis from June 2026.
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →